Hormonal
GLP-1 receptor agonists and co-agonists induce significant weight loss (10–25%) in adults without diabetes, with newer multi-agonists (e.g., tirzepatide, retatrutide) demonstrating superior efficacy compared to earlier single-agonists.
If you have obesity or overweight with related health issues, GLP-1 medications (like semaglutide or tirzepatide) are now a standard, effective treatment option that can produce significant weight loss (10-25%), comparable to surgery. Newer oral options exist, and these drugs work independently of diabetes status. Consult a doctor to see if you qualify, as they are typically reserved for those who haven't succeeded with lifestyle changes alone.
Clinical trials and real-world data have shown that these agents can induce weight loss of 10–25% from baseline in individuals without diabetes—effects that could previously only be achieved through bariatric surgery... These findings suggest that newer co-agonists may result in greater weight loss than earlier GLP-1 RAs.
Why this rating
This is a protocol for a systematic review and network meta-analysis; the results are not yet published, so the evidence quality is currently 'pending' or 'methodological promise'.
Source
The use of GLP-1 receptor agonists and co-agonists in adults without diabetes: a systematic review and network meta-analysis protocol
Areesha Moiz et al. · Systematic Reviews · 2026
DOI 10.1186/s13643-026-03153-6
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →